This site is intended for health professionals only
Sunday 15 July 2018
Share |

Topic: *** Editor's Pick

July 11, 2018
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.

The European Commission (EC) has approved a label change for Simponi (golumumab) allowing early dose optimisation in patients with ulcerative colitis (UC).
 
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.
 

July 11, 2018
The European anti-counterfeiting measures will come into force in February. Léa Legraien gives pharmacists all the information they need to make sure they’re ready

The European anti-counterfeiting measures will come into force in February. Lea Legraien gives pharmacists all the information they need to make sure they’re ready 
 
The Falsified Medicines Directive (FMD) will come into force on 9 February 2019 in the UK, as mandated by the European Commission (EC), to tackle counterfeit medicines and improve patient safety.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbation.

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

July 5, 2018
Cimzia can be used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, following label extension by European Medicines Agency (EMA)

The European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol) therapy, Belgian biopharmaceutical company UCB has announced.
 
The extension allows Cimzia’s use for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
 

July 4, 2018
A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.

A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.
 
This month [June 2 2018], the organisation announced the launch of a Phase I Clinical Trial of its lead product, Hair Stimulating Complex, to treat the condition.
 

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

June 28, 2018
First patient with metastatic breast cancer receives treatment to look at anti-tumour effect and tolerability using new drug response predictor

A drug trial on a patient with metastatic breast cancer selected by a new drug response predictor has been launched.
 

June 28, 2018
First cannabinoid prescription medicine to be approved in the US endorses Epidiolex to treat two rare forms of childhood-onset epilepsy

The first cannabinoid prescription in the US has been given the green light by the US Food and Drug Administration (FDA) [June 25 2018].
 
GW Pharmaceuticals’ Epidiolex has been approved to treat two rare forms of childhood onset epilepsy - Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome.
 

June 27, 2018
Oral Semaglutide demonstrates significant reduction in blood sugar versus placebo in trial

A once-daily tablet could reduce blood sugar in adults with type 2 diabetes, a study has shown.
 
Oral semaglutide, an investigational GLP-1 analogue from global healthcare company Novo Nordisk,achieved “significant reductions in blood sugar versus placebo in adults with type 2 diabetes”, according to the PIONEER 1 phase 3a trial.
 
The trial evaluated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo as monotherapy over 26 weeks in adults with type 2 diabetes. [1] 
 

June 26, 2018
The guidance recommends co-prescribing cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease, building on broader prescribing advice from the 2006 guidelines. A spokesperson from NICE said that the change was in response to new trials, including the DOMINO-AD trial in the UK.

The UK’s National Institute of Care and Excellence (NICE) has updated dementia guidelines to  include revised prescribing advice, new measures for patients suffering from dementia with lewy bodies (DLB) and a move to primary care treatment.
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.

Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.
 
The EC granted the company a full marketing authorisation for the drug based on the overall survival date from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (PH-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
 

June 20, 2018
Idorsia launches PRECISION – Phase 3 study with aprocitentan for resistant hypertension management in adults

Swiss biopharmaceuticals business Idorsia has announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for managing resistant hypertension in adults [June 20 2018].
 

June 19, 2018
If passed, the legislation will provide hospital pharmacists with a legal defence for inadvertent dispensing errors

The UK’s Government is consulting on proposals to decriminalise dispensing errors for hospital pharmacists and technicians, it has announced.
 
The Department of Health and Social Care (DHSC) today (19 June) published a consultation on whether it should provide a legal defence for inadvertent dispensing errors for hospital pharmacists following the passing of a similar law protecting community pharmacists in April.
 

June 14, 2018
International team of researchers have developed new DNA test to identify men at greatest risk of prostate cancer

A saliva based DNA test to identify men who are at the highest risk of developing prostate cancer is to start early trials.
 
An international team of researchers led by scientists at The Institute of Cancer Research (ICR), London, have developed the new DNA test to unearth new genetic variants that were particularly hard to find.
 

June 14, 2018
Cancer fighting effects of aspirin revealed in bowel tumour study

Taking aspirin could help to prevent bowel cancer, researchers have suggested.
 
Regular use of aspirin is known to reduce the risk of developing colon cancer but the drug’s tumour fighting properties have not been well understood. Researchers at theUniversity of Edinburgh have found that the painkiller blocks a key process linked to tumour formation, shedding light on how taking aspirin can help to stave off bowel cancer.
 

June 12, 2018
A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

 

June 6, 2018
First monoclonal antibody therapy for prevention of migraine

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Aimovig (erenumab).
 
The EMA’s Committee for Medicinal Products for Human Use (CHMP) said the drug was the first human monoclonal antibody therapy for preventing migraine.
 
Aimovig, produced by Novartis Europharm, belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP) – a molecule that is involved in migraine attacks.
 

June 6, 2018
Evidence on whether cabozantinib increases the overall length of time people live is “less certain” says the National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) has issued draft guidance rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.

 

Cabometyx (cabozantinib) is a treatment for adult patients with advanced renal cell carcinoma (RCC) following prior vascular endothelial growth factor (VEGF)-targeted therapy.

 

June 4, 2018
An antifungal medication, commonly prescribed for toenail infections, could help eliminate dormant cells within bowel tumours

An antifungal medication, commonly prescribed for toenail infections, could help eliminate dormant cells within bowel tumours, according to new research funded by Cancer Research UK and published in the Journal of Experimental Medicine on Thursday.
 
 

June 4, 2018
Tegsedi has been approved by the EMA for treatment of stage 1 and 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of its orphan drug Tegsedi™ (inotersen), for the treatment of Stage 1 or Stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR amyloidosis).1

 

 

June 4, 2018
Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangement

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the National Institute for Health and Care Excellence (NICE) will make ZEJULA®(niraparib), the first PARP inhibitor shown to be effective in patients with a BRCA mutation as well as those without a BRCA mutation, available to women in England and Wales with recurrent platinum-sensitive ovarian cancer via the Cancer Drugs Fund (CDF)[1]. 
 

June 1, 2018
Health and Social Care Committee identifies key areas associated with childhood obesity, which demand urgent attention from government

The Health and Social Care Committee has called on the UK government to make it clear that childhood obesity is “everyone’s business”.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine